Some investors shy away from buying stocks that have high prices. The belief is unfounded.
Aurobindo Pharma gained 3.7 percent after the company's US subsidiary emerged as highest bidder to acquire Natrol with bid of USD 132.5 million.
The Indian pharma sector, estimated to be around Rs 1.5 lakh crore, recorded single digit growth for the first time in several years on account of deeper price cuts under pricing policy and selective boycott of companies by the retailers.
GAIL | GSK Pharma | Axis Bank | Wipro | ICICI Bank | Larsen and Toubro | IOC | Infosys | Financial Technologies | United Spirits and United Breweries Holdings are stocks, which are in the news today.
Arvind Bothra, vice president of institutional research at Religare Capital Markets is cautious on Ranbaxy because the earnings visibility is very low and believes that the expectations of a turnaround in the US business etc are seemingly priced-in the stock.
But Daljit Singh Kohli, IndiaNivesh Securities advises investors to tender in the offer and get out.
According to Yogesh Radke, long-term retail investor can continue to hold on GSK pharma in his portfolio. Or if he wants to exit, it is better to exit onscreen rather than tendering into the offer.
Jindal Steel is the biggest loser in the Sensex, falling 3 percent followed by Hero Motocorp, Mahindra and Mahindra, Tata Steel, ONGC and Hindalco Industries with a 1-2 percent loss.
Ajay Srivastava, CEO, Dimensions Consulting recommends subscribing to the GSK Pharma open offer as he believes the drug major will look at delisting eventually.
After the UK-based parent of GSK Pharma announced an open offer proposing to buy nearly 25% of the firm at a price of Rs 3,100 per share â€“ a nearly 26% premium to the stock‘s Friday closing price, CNBC-TV18 spoke with Ranjit Kapadia, Pharma Analyst, Centrum Broking, to get his view.
GSK, which holds 50.7 percent stake, wants to raise its stake to 75 percent at a price of Rs 3,100 per share. The deal will cost the parent firm about Rs 6,400 crore or USD 1 billion.
Mastek | Ranbaxy Labs | Apollo Tyres | Tulip Telecom | Moser Baer | S Kumars Nationwide | Pipavav Defence | Hathway Cable | HCL Infosystems | Ansal Properties | Videocon Industries | Hanung Toys | Panacea Biotec | Ramky Infra | Amara Raja | Unitech | IVRCL and JP Associates are stocks, which are in the news today.
Godrej Consumer | Reliance Communications | OBC | YES Bank | Jindal Steel | IFCI | Jet Airways | Bajaj Hindusthan | Indian Hotels | Financial Technologies | IOC and Apollo Tyres are stocks, which are in the news today.
Dhampur Sugar | NCC | Gujarat Gas | Tilaknagar Industries | MOIL | Eicher Motors | GSK Pharma | Apollo Hospitals | Ranbaxy Labs | HUL | DLF | Unity Infra and BEML are stocks, which are in the news today.
GSK Pharma may rally to Rs 3000 in next two- three months, says SP Tulsian of sptulsian.com.
GSK India Plc is likely to hike its stake upto 75 percent in GSK Pharma via a voluntary open offer that will take place in the next two-three months.
Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).
Moneycontrol brings to you some of the recommendations given by experts that will help you cash in on the many opportunities available.
GlaxoSmithKline Pharmaceuticals today reported 4.44 per cent rise in net profit at Rs 152.34 crore for the quarter ended September 30, 2012 on back of robust sales.
Karvy Stock Broking has come out with its report on pharma pricing policy. The research firm initial assessment is based on a 50 % price cut and a possible 80% price cut for products marked in Light Blue. The impact based on the above methodology shows a higher impact on Sanofi Aventis, GSK Pharma, Cipla, Ranbaxy Labs.
Motilal Oswal is bullish on GlaxoSmithKline Pharmaceuticals (GLXO) and has recommended buy rating on the stock with a target price of Rs 2,272 in its February 21, 2012 research report.
PINC Research is bearish on GlaxoSmithKline Pharmaceuticals (GSK Pharma) and has recommended sell rating on the stock with a target price of Rs 1880 in its February 16, 2012 research report.
Emkay Global Financial Services has come with its December quarterly earning estimates for pharmaceutical sector. According to the research firm the sector is expected to report a growth of 18% YoY (5% QoQ) in revenues partly driven by Rupee depreciation which is likely to be 4-5% of the overall growth.
PINC Research is bearish on GSK Pharma and has recommended sell rating on the stock with a target price of Rs 1,822 in its November 4, 2011 research report.
Emkay Global Financial Services has come out with its report on various stocks. The research firm is bullish on Gujarat Gas and Bharti Airtel while bearish on GSK Pharma and has recommended reduce rating on the stock. It has a hold rating on Ashok Leyland, Manappuram General Finance in its November 4, 2011 research report.